Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Oct;58(4):410–414. doi: 10.1038/bjc.1988.231

Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.

A M Eggermont 1, P H Sugarbaker 1
PMCID: PMC2246785  PMID: 3264714

Abstract

We have previously reported on the efficacy of intraperitoneal (i.p.) immunotherapy with interleukin-2 (IL-2) and adoptively transferred lymphokine activated killer (LAK) cells in an i.p. murine tumour model. Because of a dose-limiting toxicity associated with IL-2, cures are seldom observed. The development of treatment strategies that combine components that augment or synergise with the antitumour activity of IL-2 is crucial for the successful use of IL-2 in a clinical setting. Because of the known toxicity of high-dose IL-2 or high dose cyclophosphamide (CY) treatment, the goal of our experiments was to investigate the efficacy of chemoimmunotherapy with low or moderate doses of cyclophosphamide (CY) in combination with low or moderate doses of IL-2 with or without adoptively transferred LAK cells. Assessment of i.p. tumour growth 14 days after tumour inoculation, using the peritoneal cancer index (PCI) scoring system, demonstrated that combination treatment of established (day 3) i.p. tumour was clearly superior to single modality treatment. The effect was further enhanced by a second dose of CY at the end of a course of IL-2. Combination treatment led to a significant survival benefit. About 25% of the mice were cured, even when the dose of tumour cells at inoculation was increased. These experiments demonstrate the efficacy of combined treatment with IL-2, LAK cells and CY. Further research should be directed at the design of treatment schedules based on repetitive courses of chemoimmunotherapy associated with little toxicity.

Full text

PDF
410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ades E. W., McKemie C. R., 3rd, Wright S., Peacocke N., Pantazis C., Lockhart W. L., 3rd Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activity. Nat Immun Cell Growth Regul. 1987;6(5):260–268. [PubMed] [Google Scholar]
  2. Anderson R. E., Standefer J. C., Tokuda S. The structural and functional assessment of cytotoxic injury of the immune system with particular reference to the effects of ionizing radiation and cyclophosphamide. Br J Cancer Suppl. 1986;7:140–160. [PMC free article] [PubMed] [Google Scholar]
  3. Bast R. C., Bast B. S. Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci. 1976;277(00):60–93. doi: 10.1111/j.1749-6632.1976.tb41692.x. [DOI] [PubMed] [Google Scholar]
  4. Donohue J. H., Rosenberg S. A. The fate of interleukin-2 after in vivo administration. J Immunol. 1983 May;130(5):2203–2208. [PubMed] [Google Scholar]
  5. Eggermont A. M., Marquet R. L., de Bruin R. W., Jeekel J. Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor site. Cancer Immunol Immunother. 1986;22(3):217–220. doi: 10.1007/BF00200036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eggermont A. M., Steller E. P., Matthews W., Sugarbaker P. H. Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2. Br J Cancer. 1987 Aug;56(2):97–102. doi: 10.1038/bjc.1987.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eggermont A. M., Steller E. P., Ottow R. T., Matthews W., Jr, Sugarbaker P. H. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells. J Natl Cancer Inst. 1987 Nov;79(5):983–990. [PubMed] [Google Scholar]
  8. Eggermont A. M., Sugarbaker P. H., Marquet R. L., Jeekel J. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models. Cancer Immunol Immunother. 1988;26(1):23–30. doi: 10.1007/BF00199843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ettinghausen S. E., Lipford E. H., 3rd, Mulé J. J., Rosenberg S. A. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol. 1985 Aug;135(2):1488–1497. [PubMed] [Google Scholar]
  10. GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
  11. Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985 May 1;161(5):1122–1134. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985 Aug;45(8):3735–3741. [PubMed] [Google Scholar]
  14. Li L. H., DeKoning T. F., Wallace T. L. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs. Cancer Res. 1987 Nov 15;47(22):5894–5900. [PubMed] [Google Scholar]
  15. Lotze M. T., Matory Y. L., Rayner A. A., Ettinghausen S. E., Vetto J. T., Seipp C. A., Rosenberg S. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986 Dec 15;58(12):2764–2772. doi: 10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  16. Matory Y. L., Chang A. E., Lipford E. H., 3rd, Braziel R., Hyatt C. L., McDonald H. D., Rosenberg S. A. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod. 1985 Aug;4(4):377–390. [PubMed] [Google Scholar]
  17. Mulé J. J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985 Jul;135(1):646–652. [PubMed] [Google Scholar]
  18. Mulé J. J., Shu S., Schwarz S. L., Rosenberg S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984 Sep 28;225(4669):1487–1489. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  19. North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982 Apr 1;155(4):1063–1074. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. North R. J. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol. 1984;35:89–155. doi: 10.1016/s0065-2776(08)60575-1. [DOI] [PubMed] [Google Scholar]
  21. Ottow R. T., Eggermont A. M., Steller E. P., Sugarbaker P. H. The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells. Cancer. 1987 Oct 1;60(7):1465–1473. doi: 10.1002/1097-0142(19871001)60:7<1465::aid-cncr2820600711>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  22. Ottow R. T., Steller E. P., Sugarbaker P. H., Wesley R. A., Rosenberg S. A. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol. 1987 Feb;104(2):366–376. doi: 10.1016/0008-8749(87)90038-4. [DOI] [PubMed] [Google Scholar]
  23. Papa M. Z., Mulé J. J., Rosenberg S. A. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res. 1986 Oct;46(10):4973–4978. [PubMed] [Google Scholar]
  24. Papa M. Z., Yang J. C., Vetto J. T., Shiloni E., Eisenthal A., Rosenberg S. A. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 1988 Jan 1;48(1):122–129. [PubMed] [Google Scholar]
  25. Parker G. A., Rosenberg S. A. Serologic identification of multiple tumor-associated antigens on murine sarcomas. J Natl Cancer Inst. 1977 May;58(5):1303–1309. doi: 10.1093/jnci/58.5.1303. [DOI] [PubMed] [Google Scholar]
  26. Polak L., Turk J. L. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature. 1974 Jun 14;249(458):654–656. doi: 10.1038/249654a0. [DOI] [PubMed] [Google Scholar]
  27. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  28. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  29. Sugarbaker P. H., Matthews W., Steller E. P., Eggermont A. M. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells. J Biol Response Mod. 1987 Aug;6(4):430–445. [PubMed] [Google Scholar]
  30. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES